Jack/ARNA were responsible for choosing the partner and are ultimately responsible to the shareholders for improving the stock price. The stock is down over 30% in a huge bull market for biotech. Somehow being patient is perceived as positive and wise while expecting results and participation in the bull market are considered ignorant and negative? As a shareholder I care about 1 thing- ROI. In that regard they are failing miserably.
Definition of ARNA shorts=copy poster names, copy posts, distort clinical data...
I have no idea. It might depend on which way they go, royalty or partner. If they want to partner, they have to buy in and assist with clinical costs (hopefully not late clinical dev expertise). At this stock price, I don't see how they can afford to buy in. Looks like IMGN will be a partnering and royalty company unless/until the have more cash flow, or a higher stock price, which appears not likely. Nobody wants a secondary at this price (I hope). They need to restructure, cut costs, cut fat...
ARNA seems to be very good at one or two things, mainly research and early development. In the area of Business, they are not so good. It's time they either hire a professional business leader that can restructure and get the company moving forward, or sell the company before they destroy it IMO.
IMGN is mentioned in the article, it should be linked to the stock. As per usual, one must go to the IMGN IR site aka the IV board for the link.
I think you might be a little high on the sales projection, but $1BB will get about 5-6BB in cap when verifiable, so you can do the math. If they get ADP and Scizo...might be $2BB+
sorry, but on this I tend to agree, DF is not a friend of ARNA, they are a friend of the shorts, or a short/hedged/manipulator that is holding back, or helping to hold back ARNA's share price while shorts cover.
this stock got too expensive and now it seems like all people talk about is immunotherapy and T-cells. Not sure about the LT future of ADC's.
SGEN is down 7%. I was thinking about buying some SGEN puts a few days ago to hedge IMGN/ADC risk, should have done that. It seems like everyone believes the future is with immunotherapy.
Thanks S9. ARNA doesn't appear to be in play, but the link is appreciated. ACAD and EXAS appear to be in play, or are being squeezed. I have 2 winners and 2 clunkers.
Calls are losing their bid and puts are bid. Some biotech stocks are up well on the CBST acquisition SGEN and IMGN are lagging. I think they both need to find a buyer that will invest in ADC's.
I sure hope so, but I would add NVS to the list. I would rather see a deal in the $15+ range than another dilution. If they can strike a deal for one of the pipeline products that's structured well and will lead to an acquisition after success, that would be OK. I just don't trust this management team to do the right thing for the shareholders, to make the optimal investment decisions, or to advance drugs past phase I. The sum of the parts might be worth something to someone, Roche or Sanofi can buy for their drug and decide which drugs to develop and which to sell, or partner and probably make a nice deal. The new technology might be spun into a new business, or licensed. There's potential, but IMGN is in the wrong hands and if action is not taken soon, the company could continue to decline.
DLBCL looks positive/interesting, but it's very early, very small sample size and some competition from SGEN and others that are slightly further ahead. The immunotherapy companies are getting into this area, but nothing advanced so far. I am interested to see an ADC + an Immunotherapy in some combination for something. I doubt early 529 news alone will be enough to move the stock price substantially higher. Need to hear more about SAR and BT at ASH and T-DM1 next week at SABCS to determine the direction.
I think the Marianne top line is likely to be released next week at the SABCS, full data at ASCO. ASH is for blood cancers, boy do I look ignorant.
With just a brief look through the abstracts I did not notice any great new data/info. Hoping there's more to come. BT-062 and the SAR naked antibody almost given away by IMGN both look very good, but I did not see any new, advanced trial data at least so far.
I think it would take both + Kadcyla and something very + out of ASH to get IMGN back to $14. There will be a lot of long suffering investors ready to sell if/when the stock price ever recovers. It might take an acquisition to make $14+ happen, If I had more of my $ in ACAD and EXAS and less in IMGN and ARNA I would be retiring.
or a take under/low premium deal. SEGN may be fully valued and BB's may want to cash in. Since I own IMGN, I am rooting for both to eventually be acquired and higher prices, but the relative valuations seem out of line IMO.
Thanks S9. A new partnership that infuses some cash would be a great benefit. $8 would be great. If AVNR can get to 3.5BB, ARNA can certainly get there and more at some point.
Thanks. Dates for SABCS are Dec 9-13, so we might have to sweat this out for another week. Not sure why they think positive results are baked in, the stock price/performance is terrible. If this is how it acts when + news is expected... Maybe the high option vol/pricing is based on both news expected this weekend and Marianne/SABCS.